Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor

References

• Abe T, Kinoshita T, Matsuda J, Ogushi T, Kawasugi K, Yoshimura Y, Otomo M. (1984). Phase I study of FUT-175—single and multiple dose study. Jpn Pharmacol Ther 12:65–88. [in Japanese]
   Google Scholar
• Ahmed S, Imai T, Yoshigae Y, Otagiri M. (1997). Stereospecific activity and nature of metabolizing esterases for propranolol prodrug in hairless mouse skin, liver and plasma. Life Sci 61:1879–87.
   PubMed Web of Science ®Google Scholar
• Arulmozhi DK, Portha B. (2006). GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 28:96–108.
   PubMed Web of Science ®Google Scholar
• Augustinsson KB. (1961). Multiple forms of esterase in vertebrate blood plasma. Ann NY Acad Sci 94:844–60.
   Web of Science ®Google Scholar
• Balani SK, Li P, Nguyen J, Cardoza K, Zeng H, Mu DX, Wu JT, Gan LS, Lee FW. (2004). Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab Dispos 32:1092–5.
   PubMed Web of Science ®Google Scholar
• Bálint J, Egri G, Kiss V, Gajáry A, Juvancz Z, Fogassy E. (2001). Unusual phenomena during the resolution of 6-fluoro-2-methyl-1,2,3,4-tetrahydroquinoline (FTHQ): thermodynamic-kinetic control. Tetrahedron: Asymmetry 12:3435–9.
   Google Scholar
• Banker MJ, Clark TH, Williams JA. (2003). Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92:967–74.
   PubMed Web of Science ®Google Scholar
• Berry LM, Wollenberg L, Zhao Z. (2009). Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett 3:70–7.
   PubMedGoogle Scholar
• Block W, Arndt R. (1978). Chromatographic study on the specificity of bis-p-nitrophenylphosphate in vivo. Identification of labelled proteins of rat liver after intravenous injection of bis-p-nitro[14C]phenylphosphate as carboxylesterases and amidases. Biochim Biophys Acta 524:85–93.
   PubMed Web of Science ®Google Scholar
• Bojanowska E. (2005). Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-1 in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci Monit 11:RA271–8.
   PubMed Web of Science ®Google Scholar
• Borthwick AD, Davies DE, Ertl PF, Exall AM, Haley TM, Hart GJ, Jackson DL, Parry NR, Patikis A, Trivedi N, Weingarten GG, Woolven JM. (2003). Design and synthesis of pyrrolidine-5,5′-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 4. Antiviral activity and plasma stability. J Med Chem 46:4428–49.
   PubMed Web of Science ®Google Scholar
• Borthwick AD, Exall AM, Haley TM, Jackson DL, Mason AM, Weingarten GG. (2002). Pyrrolidine-5,5-trans-lactams as novel mechanism-based inhibitors of human cytomegalovirus protease. Part 3: potency and plasma stability. Bioorg Med Chem Lett 12:1719–22.
   PubMed Web of Science ®Google Scholar
• Boyce JM, Wright FJ, Cervenko FW, Pietak SP, Faulkner S. (1976). Prolongation of anesthetic action by BNPP (bis-[p-nitrophenyl]phosphate) Anesthesiology 45:629–34.
   PubMed Web of Science ®Google Scholar
• Brandt E, Hyemann E, Mentlein R. (1980). Selective inhibition of rat liver carboxylesterases by various organophosphorus diesters in vivo and in vitro. Biochem Pharmacol 29:1927–31.
   PubMed Web of Science ®Google Scholar
• Breitenlechner CB, Wegge T, Berillon L, Graul K, Marzenell K, Friebe WG, Thomas U, Schumacher R, Huber R, Engh RA, Masjost B. (2004). Structure-based optimization of novel azepane derivatives as PKB inhibitors. J Med Chem 47:1375–90.
   PubMed Web of Science ®Google Scholar
• Brown AM. (2005). HERG block, QT liability and sudden cardiac death. Novartis Found Symp 266:118–31.
   PubMedGoogle Scholar
• Di L, Kerns EH, Hong Y, Chen H. (2005). Development and application of high throughput plasma stability assay for drug discovery. Int J Pharm 297:110–119.
   PubMed Web of Science ®Google Scholar
• Ecobichon DJ. (1970). Characterization of the esterases of canine serum. Can J Biochem 48:1359–67.
   PubMedGoogle Scholar
• Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, Vimal M, Szewczyk GR, Jayawickreme C, Moncol DL, Rimele TJ, Armour SL, Weaver SP, Griffin RJ, Tadepalli SM, Jeune MR, Shearer TW, Chen ZB, Chen L, Anderson DL, Becherer JD, De Los Frailes M, Colilla FJ. (2009). Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J Med Chem 52:7962–5.
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Palladino G, Cipriani S. (2009). Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 30:570–80.
   PubMed Web of Science ®Google Scholar
• Frank N, Caesar R, Scherf HR, Wiessler M. (1986). Influence of the carboxylesterase inhibitor bis-p-nitrophenylphosphate on the rates of hydrolysis of various α-esters of 1-(N-methyl-N-nitrosoamino)-methanol in vitro and in vivo and on the acute toxicity and carcinogenicity of 1-(N-methyl-N-nitrosamino)-methylacetate. J Cancer Res Clin Oncol 111:98– 102.
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Dolgos H, Gillberg P-G Bredberg, U, Benthem B, Duker G. (2009). Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discovery Today 14:358–72.
   PubMed Web of Science ®Google Scholar
• Gabrielsson J, Green AR. (2009). Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331:767–74.
   PubMed Web of Science ®Google Scholar
• Hamada Y, Ohtake J, Sohma SY, Kimura T, Hayashi Y, Kiso Y. (2002). New water-soluble prodrugs of HIV protease inhibitors based on O → N intramolecular acyl migration. Bioorg Med Chem 10:4155–67.
   PubMed Web of Science ®Google Scholar
• Heymann E, Krisch K. (1967). [Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases] Hoppe-Seyler’s Z Physiol Chem 348:609–619.
   PubMedGoogle Scholar
• Heymann E, Krisch K, Büch H, Buzello W. (1969). Inhibition of phenacetin- and acetanilide-induced methemoglobinemia in the rat by the carboxylesterase inhibitor bis-[p-nitrophenyl]phosphate. Biochem Pharmacol 18:801–11.
   PubMed Web of Science ®Google Scholar
• Heymann E, Mentlein R, Schmalz R, Schwabe C, Wagenmann F. (1979). A method for the estimation of esterase synthesis and degradation and its application to evaluate the influence of insulin and glucagon. Eur J Biochem 102:509–14.
   PubMedGoogle Scholar
• Holmes RS, Masters CJ. (1967). The developmental multiplicity and isoenzyme status of cavian esterases. Biochim Biophys Acta 132:379–99.
   PubMed Web of Science ®Google Scholar
• Ito F, Hard N, Kobayashi H, Kanzaki N. (2006). Japanese Patent Application, JP 2006/063064.
   Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. (1998). Prediction of pharmacokinetic alterations caused by drug–drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387–411.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Nguyen HT. (2004). Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event. Drug Metab Dispos 32:943–52.
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS. (2002). Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–38.
   PubMed Web of Science ®Google Scholar
• Katsuma S, Hirasawa A, Tsujimoto G. (2005). Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329:386–90.
   PubMed Web of Science ®Google Scholar
• Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, Xiao HY, Lu S, Qian L, Han WC, Shan W, Mitt T, Cai ZW, Poss MA, Zhu H, Sack JS, Tokarski JS, Chang CY, Pavletich N, Kamath A, Humphreys WG, Marathe P, Bursuker I, Kellar KA, Roongta U, Batorsky R, Mulheron JG, Bol D, Fairchild CR, Lee FY, Webster KR. (2002). Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 45:3905–27.
   PubMed Web of Science ®Google Scholar
• Lee K, Park SK, Kwon BM, Kim K, Yu HE, Ryu J, Oh SJ, Lee KS, Kang JS, Lee CW, Kwon MG, Kim HM. (2009). Transport and metabolism of the antitumour drug candidate 2′-benzoyloxycinnamaldehyde in Caco-2 cells. Xenobiotica 39:881–88.
   PubMed Web of Science ®Google Scholar
• Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84.
   PubMed Web of Science ®Google Scholar
• Li P, Callery PS, Gan LS, Balani SK. (2007). Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos 35:1203–8.
   PubMed Web of Science ®Google Scholar
• Linder CD, Renaud NA, Hutzler JM. (2009). Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos 37:10–13.
   PubMed Web of Science ®Google Scholar
• Maurer TS, Debartolo DB, Tess DA, Scott DO. (2005). Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175–81.
   PubMed Web of Science ®Google Scholar
• Minagawa T, Kohno Y, Suwa T, Tsuji A. (1995). Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 49:1361–5.
   PubMed Web of Science ®Google Scholar
• Mugford CA, Mortillo M, Mico BA, Tarloff JB. (1992). 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague–Dawley rats. Fundam Appl Toxicol 19:43–9.
   PubMedGoogle Scholar
• Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estrabrook RW, Gunsalus IC, Nebert DW. (1996). P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmcogenetics 6:1–42.
   PubMedGoogle Scholar
• Ohura K, Sakamoto H, Ninomiya SI, Imai T. (2010). Development of a novel system for estimating human intestinal absorption using Caco-2 cells in the absence of esterase activity. Drug Metab Dispos 38:323–31
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Viani A. (1992). Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 23:449–68.
   PubMed Web of Science ®Google Scholar
• Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, Saladin R, Schoonjans K, Pellicciari R, Auwerx J. (2008). Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure–activity relationships, and molecular modeling studies. J Med Chem 51:1831–41.
   PubMed Web of Science ®Google Scholar
• Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, Nagai E. (1994). Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662–4.
   PubMed Web of Science ®Google Scholar
• Schuhmacher J, Kohlsdorfer C, Buhner K, Brandenburger T, Kruk R. (2004). High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 93:816–30.
   PubMed Web of Science ®Google Scholar
• Sertkaya NN, Gorrod JW. (1988). In vitro deacetylation studies with isomeric acetamidobiphenyls using selective carboxylesterase inhibitors. Anticancer Res 8:1345–50.
   PubMed Web of Science ®Google Scholar
• Strelevitz TJ, Foti RS, Fisher MB. (2006). In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334–41.
   PubMed Web of Science ®Google Scholar
• Tafazoli S, Mashregi M, O’Brien PJ. (2008). Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol Appl Pharmacol 229:94–101.
   PubMed Web of Science ®Google Scholar
• Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. (2008). Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discovery 7:678–93.
   PubMed Web of Science ®Google Scholar
• Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata YT, Inoue H. (2009). In vitro stability and metabolism of salvinorin A in rat plasma. Xenobiotica 39(5):391–8.
   PubMed Web of Science ®Google Scholar
• von Deimling O, Boecking A. (1976). Esterases in histochemistry and ultrahistochemistry. Histochem J 8:215–20.
   PubMedGoogle Scholar
• Xie M, Yang D, Liu L, Xue B, Yan B. (2002). Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab Dispos 30:541–7.
   PubMed Web of Science ®Google Scholar
• Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, Sone T, Isobe M, Ohshima T, Matsumura K, Oda M, Watanabe K. (2006). Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. Drug Metab Pharmacokinet 21:147–55.
   PubMed Web of Science ®Google Scholar
• Yoshigae Y, Imai T, Taketani M, Otagiri M. (1999). Characterization of esterases involved in the stereoselective hydrolysis of ester-type prodrugs of propranolol in rat liver and plasma. Chirality 11:10–13.
   PubMed Web of Science ®Google Scholar
• Zhu M, Zhang D, Zhang H, Shyu WC. (2009). Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations. Biopharm Drug Dispos 30:163–84.
   PubMed Web of Science ®Google Scholar